Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Press release Exhibit 99.1 contains the reported financial figures and management commentary
Item 7.01 · Regulation FD Disclosure
- Xenon designates its website, investor-relations site, news releases, X account, and LinkedIn as channels for potentially material disclosures
- Investors should monitor these channels alongside SEC filings for updates on product candidates and corporate developments
Item EX-99.1 · Exhibit EX-99.1
- FDA NDA for azetukalner in focal seizures submitted September 2026, advancing Xenon toward potential commercialization
- X-NOVA2 MDD enrollment completed at approximately 360 patients, with topline results expected December 2026
- Cash, equivalents and marketable securities $1,153.5M, supporting operations into 2029 without near-term financing pressure
- Q3 net loss $110.4M versus $90.9M, driven by higher clinical, manufacturing and personnel costs
- Phase 2 acute-pain studies for XEN1701 and XEN1120 planned for H1 2027 after positive Phase 1 data
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.